PR98586

New York , Nov. 8, 2022 /PRNewswire=KYODO JBN/ --

Agreement includes aggregate upfront and target nomination fees of up to $21.5

million for up to 6 targets, and additional R&D and sales milestones plus

tier-based mid-single- to low double-digit royalties.

Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug

discovery company, announced a multi-year, multi-target strategic research

collaboration with Sanofi. Under the terms of the agreement, the collaboration

will leverage Insilico Medicine's AI platform, Pharma.AI, to advance drug

development candidates for up to six new targets.

"We look forward to working with Insilico Medicine, a demonstrated leader in

AI-powered drug discovery," said Changchun Xiao, Head of China Research at

Sanofi. "This collaboration will leverage our complementary capabilities, as

well as the co-location of our scientific teams, to boost the drug discovery

efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi's R&D

center in China."

Under the terms of the agreement, Sanofi will pay Insilico Medicine a total of

up to $21.5 million covering the upfront and target nomination fees to benefit

from Insilico's end-to-end Pharma.AI platform and gain access to a team of

interdisciplinary drug discovery scientists to identify, synthesize, and

advance high-quality lead therapeutic compounds up to development candidate

stage. Additional payments will be made if key research, development, and sales

milestones are met, and could total more than $1.2 billion. The collaboration

also establishes mid-single to up to low double-digit tiered royalties for any

products developed.

"We are very happy to collaborate with Sanofi, a company with a clear strategy

in AI-powered drug discovery," said Alex Zhavoronkov, PhD, CEO and founder of

Insilico Medicine. "This close collaboration will allow Sanofi to immediately

gain the capabilities of one of the top AI startups in addition to enriching

their drug discovery pipeline."

"We are thrilled to collaborate with Sanofi. Leveraging Sanofi's strong drug

research and development expertise and Insilico's powerful AI platform, we

believe we can accelerate novel therapeutics discovery to address diseases with

unmet medical needs," said Feng Ren, PhD, co-CEO and Chief Scientific Officer

of Insilico Medicine. "Together we will use cutting-edge AI technologies to

make significant breakthroughs in drug R&D."

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence

(AI)-driven drug discovery company, is   connecting biology, chemistry, and

clinical trials analysis using next-generation AI systems. The company has

developed AI platforms that utilize deep generative models, reinforcement

learning, transformers, and other modern machine learning techniques to

discover novel targets and to design novel molecular structures with desired

properties. Insilico Medicine is delivering breakthrough solutions to discover

and develop innovative drugs for cancer, fibrosis, immunity, central nervous

system (CNS) diseases and aging-related diseases.

For more information, visit www.insilico.com 　 

For business development inquiries, contact bd@insilicomedicine.com

Source: Insilico Medicine